MRK - all fair points, though I'm much more bullish about PD1+chemo uptake. Remember that the OS curve in KN021G was still quite immature, and the ORR is higher for Keytruda + chemo in the <1% patients than it is for Keytruda alone in >50%.
MRK—I expect some younger, healthier patients will opt for Keytruda + chemo in first-line NSCLC even if they technically qualify for Keytruda monotherapy. No reason for third-party payers to oppose this insofar as the chemo drugs in question are cheap generics.
Market Data 
Markets 
AI
